Shots:
- The US FDA has received BLA for TrenibotE (botulinum neurotoxin serotype E) for the treatment of mod. to sev. glabellar lines
- BLA was supported by 2 pivotal P-III (M21-500 & M21-508) trials & an open-label P-III (M21-509) safety study assessing TrenibotE in over 2,100 pts
- Trials met their 1 & 2EPs, with onset of action as early as 8hrs. post drug administration & observed efficacy duration for 2-3wks.; topline data from pivotal studies was previously shared
Ref: AbbVie | Image: AbbVie
Related News:- AbbVie Reports P-III (MIRASOL) Trial Data of Elahere for FRα-Positive Platinum-Resistant Ovarian Cancer (PROC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
